Liver fibrosis often develops without symptoms and has no approved cure. But researchers at the University of Sunderland have ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group. Perspective from Kenneth Cusi, MD, FACP, FACE Once-weekly semaglutide 2.4 mg significantly reduced ...

“The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging and management of liver fibrosis,” Roche Diagnostics CEO Matt Sause said in a statement. “With MASLD affecting a ...

A new study published in the journal of BMC Endocrine Disorders showed that increasing estimated glucose disposal rate (eGDR) ...

A recent Chinese clinical trial published in The BMJ reveals that dapagliflozin, a type 2 diabetes drug, shows promise in ...

Roche Diagnostics CEO Matt Sause said: "The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging, and management of liver fibrosis. "With MASLD affecting a growing number of ...

Discover a study that suggest efruxifermin may offer delayed therapeutic benefits for patients with MASH-related cirrhosis.

001). According to the researchers, these findings demonstrate how semaglutide can benefit patients with MASH and stage 2 or 3 liver fibrosis but warrant further and more diverse research before ...